Drug Trial Radar · NCT00123916
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Last checked: Nov 20, 2026Latest source record: Mar 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,854
Actual
Start
Nov 2004
Primary completion
Jul 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Population Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); World Health Organization; Instituto Dante Pazzanese de Cardiologia; University of Sao Paulo
- First posted
- Jul 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.
Conditions
- Chagas Disease
- Trypanosomiasis
- Heart Disease
Interventions
BenznidazoleDrug
Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
PlaceboDrug
a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.Time frame: through study completion, an average of 5 years
Locations
47 sites in 5 countries. Site status is shown where the registry gives one.
BENEFIT Investigational Site
Buenos Aires, Argentina
BENEFIT Investigational Site
Salta, Argentina
BENEFIT Ivestigational Site
Buenos Aires, Apital Federal, Argentina
BENEFIT Investigational Site
Belen de Escobar, Buenos Aires, Argentina
BENEFIT Investigational Site
Isidro Casanova, Buenos Aires, Argentina
BENEFIT Investigational Site
San Juan, Buenos Aires, Argentina
BENEFIT Investigational Site
Santiago Del Estero, Buenos Aires, Argentina
BENEFIT Investigational Site
Santiago Del Estero, Buenos Aires, Argentina
BENEFIT Investigational Site
Buenos Aires, Buenos Aires F.D., Argentina
BENEFIT Investigational Site
Catamarca, Catamarca Province, Argentina
BENEFIT Investigational Site
Charata, Chaco Province, Argentina
BENEFIT Investigational Site
Paraná, Entre Ríos Province, Argentina
BENEFIT Investigational Site
Buenos Aires, General Rodríguez Partido, Argentina
BENEFIT Investigational Site
San Salvador de Jujuy, Jujuy Province, Argentina
BENEFIT Investigational Site
Corrientes, Rosario, Santa Fe, Argentina
BENEFIT Investigational Site
Rosario, Santa Fe Province, Argentina
BENEFIT Investigational Site
Anatuya, Santiago del Estero Province, Argentina
BENEFIT Investigational Site
Santiago del Estero, Sgo. Del Estero, Argentina
BENEFIT Investigational Site
Tupiza, Potosí Department, Bolivia
BENEFIT Investigational Site
Rio de Janeiro, Brazil
BENEFIT Investigational Site
Rio de Janeiro, Brazil
BENEFIT Investigational Site
São Paulo, Brazil
BENEFIT Investigational Site
São Paulo, Brazil
BENEFIT Investigational Site
São Paulo, Brazil
BENEFIT Investigational Site
São Paulo, Brazil
BENEFIT Investigational Site
Salvador, Bahaia, Brazil
BENEFIT Investigational Site
Salvador, Bahaia, Brazil
BENEFIT Investigational Site
Salvador, Bahaia, Brazil
BENEFIT Investigational Site
Carmo, Belo Horizonte, Brazil
BENEFIT Investigational Site
Brasília, Brazilian Federal District, Brazil
BENEFIT Investigational Site
Goiânia, Goiás, Brazil
BENEFIT Investigational Site
Goiânia, Goiás, Brazil
BENEFIT Investigational Site
Goiânia, Goiás, Brazil
BENEFIT Investigational Site
Uberaba, Minas Gerais, Brazil
BENEFIT Investigational Site
Uberlândia, Minas Gerais, Brazil
BENEFIT Investigational Site
Uberlândia, Minas Gerais, Brazil
BENEFIT Investigational Site
Curitiba, Paraná, Brazil
BENEFIT Investigational Site
Recife, Pernambuco, Brazil
BENEFIT Investigational Site
Pelotas, Rio Grande do Sul, Brazil
BENEFIT Investigational Site
Campinas, São Paulo, Brazil
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.